Lilly Asia Ventures
Li Xu, M.D., is a Venture Partner with Lilly Asia Ventures (LAV). Prior to joining LAV, Li was Vice President and Head of Oncology at Hengrui, and prior to that, Vice President of Global Strategy at Pfizer. Li’s previous experience also includes Merck and Immunomedics. Li is a trained surgical oncologist who completed fellowship training at the Memorial Sloan Kettering cancer center, and also holds an M.D. from Shandong Medical University and M.B.A. from Fairleigh Dickenson.
This person is not in any offices
Lilly Asia Ventures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Originated in 2008 as a corporate venture subsidiary of Eli Lilly, they spun off and became an independent investment management company. As one of the earliest biomedical venture investors in China, they have been consistently investing in the region for over a decade, and have recently increased our footprint in the U.S. Our team of over 30 distinguished scientific, medical, investment, and operational professionals embrace a culture of integrity, entrepreneurship, and team work. Currently, they manage over $1.2 billion of committed capital.